References
1.Libby P, Luscher T. COVID-19 is, in the end, an endothelial disease,Eur Heart J. 2020;41:3038-3044.
doi: 10.1093/eurheartj/ehaa623
2. Martin JH, Head R. A pharmacological framework for integrating
treating the host, drug repurposing and the damage response framework in
COVID-19. Br J Clin Pharmacol. 2021 Mar;87:875-885. doi:
10.1111/bcp.14551
3. Jensen MP, George M, Gilroy D, Sofat R. Beyond dexamethasone,
emerging immuno-thrombotic therapies for COVID-19. Br J Clin
Pharmacol. 2021 Mar;87:845-857. doi: 10.1111/bcp.14540
4. Fedson DS. Treating the host response to emerging virus diseases:
lessons learned from sepsis, pneumonia, influenza and Ebola. Ann
Transl Med. 2016;4:421. doi: 10.21037/atm.2016.11.03
5. Iqbal Z, Ho JH, Adam S, et al. Managing hyperlipidaemia in patients
with COVID-19 and during its pandemic: An expert panel position
statement from HEART UK. Atherosclerosis. 2020;313:126-136. doi:
10.1016/j.atherosclerosis.2020.09.008
6. Cubeddu LX, Seamon MJ. Statin withdrawal: clinical implications and
molecular mecha- nisms. Pharmacotherapy. 2006;26:1288-1296. doi:
10.1592/phco.26.9.1288
7. Fonarow GC, Wright RS, Spencer FA, et al. Effect of statin use within
the first 24 hours of admission for acute myocardial infarction on early
morbidity and mortality. Am J Cardiol. 2005;96:611–616. doi:
10.1016/j.amjcard.2005.04.029
8. Torres-Pena
JD, Perez-Belmonte LM, Fuentes-Jimenez
F, et al. Prior treatment with statins is associated with improved
outcomes of patients with COVID-19: Data from the SEMI-COVID-19
Registry. Drugs. 2021 Mar 29;1-11. doi:
10.1007/s40265-021-01498-x
9. Memel ZN, Lee JJ, Foulkes AS, Chung RT, Thaweethai T, Bloom PP.
Statins are associated with improved 28-day mortality in patients
hospitalized with SARS-CoV-2 infection. medRxiv. 2021 Apr
6;2021.03.27.21254373. doi: 10.1101/2021.03.27.21254373
10. Gupta A, Madhavan MV, Poterucha TJ, et al. Association between
antecedent statin use and decreased mortality in hospitalized patients
with COVID-19. Nat Commun. 2021 Feb 26;12:1325. doi:
10.1038/s41467-021-21553-1
11. McCarthy CP, Murphy S, Jones-O’Connor M, et al. Early clinical and
sociodemographic experience with patients hospitalized with COVID-19 at
a large American healthcare system.EclinicalMedicine. 2020;26:100504. doi:
10.1016/j.eclinm.2020.100504
12. De Spiegeleer A, Bronselaer A, Teo JT, et al. The effects of ARBs,
ACEis, and statins on clinical outcomes of COVID-19 infection among
nursing home residents. J Am Med Dir Assoc. 2020
Jul;21:909-914.e2. doi: 10.1016/j.jamda.2020.06.018
13. Koh KK, Sakuma I, Shimada K, Hayashi T, Quon MJ. Combining potent
statin therapy with other drugs to optimize simultaneous cardiovascular
and metabolic benefits while minimizing adverse events. Korean
Circ J. 2017;47:432-439. doi: 10.4070/kcj.2016.0406
14. Byttebier G, Belmans L, Alexander M, et al. Hospital mortality in
COVID-19 patients in Belgium treated with statins, ACE inhibitors and
ARBs. Hum Vaccin Immunother. 2021;to be published.
15. Varshney AS, Wang DE, Bhatt AS, et al. Characteristics of clinical
trials evaluating cardiovascular therapies for Coronavirus Disease 2019
registered on ClinicalTrials.gov: a cross-sectional analysis. Am
Heart J. 2021;232:105-115. doi: 10.1016/j.ahj.2020.10.065